Abstract:Background Cell therapy of diabetes aims at restoring the physiological control of blood glucose by transplantation of functional pancreatic islet cells. A potentially unlimited source of cells for such transplantations would be islet cells derived from an in vitro differentiation of human pluripotent stem cells (hESC/hiPSC). The islet-like clusters (ILC) produced by the known differentiation protocols contain various cell populations. Among these, the β-cells that express both insulin and the transcription factor Nkx6.1 seem to be the most efficient to restore normoglycemia in diabetes animal models. Our aim was to find markers allowing selection of these efficient cells. Methods Functional Cell-Capture Screening (FCCS) was used to identify markers that preferentially capture the cells expressing both insulin and Nkx6.1, from hESC-derived ILC cells. In order to test whether selection for such markers could improve cell therapy in diabetic mouse models, we used ILC produced from a clinical-grade line of hESC by a refined differentiation protocol adapted to up-scalable bioreactors. Re-aggregated MACS sorted cells were encapsulated in microspheres made of alginate modified to reduce foreign body reaction. Implantation was done intraperitoneally in STZ-treated C57BL/6 immuno-competent mice. Results CD49A (integrin alpha1) was identified by FCCS as a marker for cells that express insulin (or C-peptide) as well as Nkx6.1 in ILC derived by hESC differentiation. The ILC fraction enriched in CD49A + cells rapidly reduced glycemia when implanted in diabetic mice, whereas mice receiving the CD49A depleted population remained highly diabetic. CD49A-enriched ILC cells also produced higher levels of human C-peptide in the blood of transplanted mice. However, the difference between CD49A-enriched and total ILC cells remained small. Another marker, CD26 (DPP4), was identified by FCCS as binding insulin-expressing cells which are Nkx6.1 negative. Depletion of CD26 + cells followed by enrichment for CD49A + cells increased insulin + /Nkx6.1 + cells fraction to ~70%. The CD26 - /CD49A + enriched ILC exhibited improved function over non-sorted ILC or CD49A + cells in diabetic mice and maintain prolonged blood C-peptide levels. Conclusions Refining the composition of ILC differentiated from hPSC by negative selection to remove cells expressing CD26 and positive selection for CD49A expressing cells could enable more effective cell therapy of diabetes.

IAPP Marks Mono-hormonal Stem-cell Derived β Cells that Maintain Stable Insulin Production and

IAPP Marks Mono-hormonal Stem-cell Derived β Cells that Maintain Stable Insulin Production in vitro and in vivo

An INSULIN and IAPP dual reporter enables tracking of functional maturation of stem cell-derived insulin producing cells

Cell identity dynamics and insight into insulin secretagogues when employing stem cell-derived islets for disease modeling

Efficient vascular and neural engraftment of stem cell-derived islets

Selection for CD26− and CD49A+ Cells From Pluripotent Stem Cells-Derived Islet-Like Clusters Improves Therapeutic Activity in Diabetic Mice

Differentiation of Sendai Virus-Reprogrammed iPSC into β Cells, Compared with Human Pancreatic Islets and Immortalized β Cell Line

Applications of iPSC-derived beta cells from patients with diabetes

Limitations in mitochondrial programming restrain the differentiation and maturation of human stem cell-derived β cells

Conformal Coating of Stem Cell-Derived Islets for β Cell Replacement in Type 1 Diabetes

Pancreatic Islet Cell Therapy for Type I Diabetes: Understanding the Effects of Glucose Stimulation on Islets in Order to Produce Better Islets for Transplantation

Comparative and integrative single cell analysis reveals new insights into the transcriptional immaturity of stem cell-derived β cells

Controlling human stem cell-derived islet composition using magnetic sorting

Secretome analysis of human and rat pancreatic islets co-cultured with adipose-derived stromal cells reveals a signature with enhanced regenerative capacities

The future treatment for type 1 diabetes: Pig islet- or stem cell-derived β cells?

Single-nucleus multi-omics of human stem cell-derived islets identifies deficiencies in lineage specification

In depth functional characterization of human induced pluripotent stem cell-derived beta cells in vitro and in vivo

Human amniotic mesenchymal stem cell-islet organoids enhance the efficiency of islet engraftment in a mouse diabetes model

IAPP-induced beta cell stress recapitulates the islet transcriptome in type 2 diabetes

In Vivo And In Vitro Characterization Of Insulin-Producing Cells Obtained From Murine Bone Marrow

Resolving human α versus β cell fate allocation for the generation of stem cell-derived islets